Education
About Us
Working with TipRanks
Follow Us
Microbix Biosystms J (TSE:MBX)
TSX:MBX
MBX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.29 - C$0.55
Previous CloseN/A
Volume37.35K
Average Volume (3M)158.09K
Market Cap
C$58.08M
Enterprise ValueC$39.16M
Total Cash (Recent Filing)C$13.05M
Total Debt (Recent Filing)C$6.44M
Price to Earnings (P/E)28.9
Beta-0.07
Next Earnings
May 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding141,666,440
10 Day Avg. Volume101,266
30 Day Avg. Volume158,086
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.45
Price to Cash Flow (P/CF)17.80
P/FCF Ratio23.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.90Price Target Upside119.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Microbix Biosystms News
PremiumCompany Announcements
Microbix Biosystems Announces Successful Shareholder Meeting Outcomes
PremiumCompany Announcements
Microbix Optimizes Capital Structure for Greater Financial Flexibility
PremiumCompany Announcements
Microbix Partners with ACPCC to Combat Cervical Cancer in Indo-Pacific
PremiumCompany Announcements
Microbix Hosts Ontario Premier, Showcases Innovations in Life Sciences
PremiumCompany Announcements
Microbix Biosystems Issues Stock Options to Retain Key Personnel
PremiumCompany Announcements
Microbix Engages Investors at Whistler Capital Event 2025PremiumCompany Announcements
Microbix Biosystems Earnings Call: Growth and Strategic AdvancesPremiumCompany Announcements
Microbix Biosystems Achieves Strong Q1 Financial Performance---
Bulls Say, Bears Say
Bulls Say
Antigen SalesAntigen revenues increased 118% Y/Y to $4.3M.
Financial PerformanceMicrobix reported FY1Q-2025 financials beating Bloom Burton’s estimates.
Bears Say
Revenue DeclineTotal revenues declined 28% Y/Y.
---
Options Prices
Currently, No data available
---
Ownership Overview
15.17% Insiders
―
Mutual Funds
― Other Institutional Investors
84.83% Public Companies and
Individual Investors
MBX FAQ
What was Microbix Biosystms J’s price range in the past 12 months?
Microbix Biosystms J lowest stock price was C$0.29 and its highest was C$0.55 in the past 12 months.
What is Microbix Biosystms J’s market cap?
Microbix Biosystms J’s market cap is C$58.08M.
When is Microbix Biosystms J’s upcoming earnings report date?
Microbix Biosystms J’s upcoming earnings report date is May 14, 2025 which is in 44 days.
How were Microbix Biosystms J’s earnings last quarter?
Microbix Biosystms J released its earnings results on Feb 13, 2025. The company reported C$0.006 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.006.
Is Microbix Biosystms J overvalued?
According to Wall Street analysts Microbix Biosystms J’s price is currently Undervalued.
Does Microbix Biosystms J pay dividends?
Microbix Biosystms J does not currently pay dividends.
What is Microbix Biosystms J’s EPS estimate?
Microbix Biosystms J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microbix Biosystms J have?
Microbix Biosystms J has 141,666,440 shares outstanding.
What happened to Microbix Biosystms J’s price movement after its last earnings report?
Microbix Biosystms J reported an EPS of C$0.006 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Microbix Biosystms J?
Currently, no hedge funds are holding shares in TSE:MBX
---
Microbix Biosystms Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$0.90 (119.51% Upside)
C$0.90 (119.51% Upside)
Insider Transactions
Sold Shares
Worth C$665.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.32%
12-Months-Change
Fundamentals
Return on Equity
6.85%
Trailing 12-Months
Asset Growth
7.06%
Trailing 12-Months
Company Description
Microbix Biosystms J
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
---
MBX Stock 12 Month Forecast
Average Price Target
C$0.90
▲(119.51% Upside)
Technical Analysis
Biome Grow Inc
―
THC Biomed INTL
―
HLS Therapeutics Inc
―
Premier Health of America Inc
―
Best Analysts Covering MBX
1 Year
1 Year Success Rate
5/6 ratings generated profit
1 Year Average Return
+9.32%
reiterated a buy rating 2 months ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +9.32% per trade.
---